AstraZeneca Files Patent Infringement Suits Against Seven Generic Drugmakers Over Crestor
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine companies in all have filed ANDAs with Paragraph IV certification against a Crestor patent, but two indicated they will not launch generic rosuvastatin prior to the patent’s expiry, AstraZeneca tells DAILY.
You may also be interested in...
Cobalt Files ANDA For AstraZeneca’s Crestor
Cobalt seeks to market generic rosuvastatin in 5, 10, 20 and 40 mg doses, firm says in an Oct. 30 letter to AstraZeneca.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.